News for MannKind Corporation (MNKD)

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation ( MNKD), a company focused on the development and commercia

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where MannKind Corporation (NASDAQ:MNKD) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology Market […]

Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation ( MNKD), announced today that its first quarter 2025 finan

Cusick. Motorsports Founder and CEO Don Cusick announced three key partners joining the team for the 109th Indianapolis 500 at the Indianapolis Motor Speedway this year.

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where MannKind Corp. (NASDAQ:MNKD) stands against other biotech penny stocks. Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of the […]

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Mizuho has begun coverage of MannKind Corporation (MNKD) with an optimistic

**media[588278,588279,588280]**

PR NewswireFRAMINGHAM, Mass., March 21, 2025 Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025As part of

Five presentations affirm positive outcomes utilizing inhaled insulinAn sNDA filing for Afrezza in pediatric population anticipated in 2025 DANBURY, Conn. and

Strength: MannKind Corp's innovative inhaled insulin product, Afrezza, and V-Go wearable insulin delivery device offer unique value propositions in the diabete

MannKind Corporation (NASDAQ:MNKD) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ETCorporate ParticipantsMichael Castagna - Chief Executive...

Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Shares of Mannkind (MNKD) rose 7% in post-market trading Wednesday after the company issued its Q4 earnings report and a business update. Read more here.

Discover MannKind's Q4 earnings results on Feb 26! Analysts predict $0.03 EPS (+50% Y/Y) & $74.99M revenue (+28.3%).

Get a deeper insight into the potential performance of MannKind (MNKD) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

**media[544997]**

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation ( MNKD), a company focused on the development and commerci